8-K: Bionomics and Neuphoria Amend Scheme Agreement, Set Shareholder Vote for December 12

Bionomics Limited and Neuphoria Therapeutics Inc. have amended their scheme implementation agreement, adjusting the exchange ratio and setting a shareholder vote for December 12, 2024, to approve the re-domiciliation to the U.S.

Summary

• Bionomics Limited and Neuphoria Therapeutics Inc. have amended their Scheme Implementation Agreement to adjust the exchange ratio for the proposed re-domiciliation.
• Holders of Bionomics ordinary shares will now receive one Neuphoria share for every 2,160 Bionomics shares.
• Holders of Bionomics American Depositary Shares (ADSs) will receive one Neuphoria share for every 12 Bionomics ADSs.
• A Scheme Meeting for Bionomics shareholders to vote on the proposed Scheme is scheduled for December 12, 2024.
• The Supreme Court of New South Wales has approved the convening of the Scheme Meeting and the distribution of the Scheme Booklet.
• Small Parcel Holders, those with fewer than 200,000 Bionomics shares, have the option to participate in a Sale Facility where their Neuphoria shares will be sold by a US broker and the proceeds remitted to them.
• The Scheme Booklet, including the Independent Expert's Report, will be dispatched to Bionomics shareholders around November 13, 2024, and is available on the Bionomics website.

Sentiment

Score: 7

Explanation: The document is generally positive, outlining the steps for a strategic re-domiciliation and providing a clear path forward. The unanimous recommendation from the board and the inclusion of an independent expert's report add to the positive sentiment. However, the inherent risks of such a transaction and the uncertainty of future share prices temper the overall sentiment.

Positives

• The Bionomics Directors unanimously recommend that shareholders vote in favor of the Scheme.
• The Scheme provides a Sale Facility for Small Parcel Holders to easily liquidate their Neuphoria shares.
• The Scheme is intended to facilitate a re-domiciliation to the U.S., which may increase the company's attractiveness to U.S. investors and strategic partners.

Risks

• The Scheme is subject to shareholder and court approval.
• The value of Neuphoria shares after the re-domiciliation is uncertain.
• There is a risk that the Scheme may not be implemented if conditions are not met or if the Scheme Implementation Agreement is terminated.

Future Outlook

The company expects to complete the re-domiciliation to the U.S. upon shareholder and court approval, with Neuphoria shares expected to trade on Nasdaq.

Management Comments

• The Bionomics Directors continue to unanimously recommend that Bionomics shareholders vote in favour of the Scheme, subject to the Independent Expert continuing to conclude that the Scheme is in the best interests of Bionomics shareholders.
• Each Bionomics Director intends to vote, or procure the voting of all of their Bionomics Shares, in which he or she has a relevant interest, in favour of the Scheme, subject to the Independent Expert continuing to conclude that the Scheme is in the best interests of Bionomics shareholders.

Industry Context

The re-domiciliation is intended to align Bionomics more closely with other prominent US pharmaceutical companies and increase its attractiveness to US investors and strategic partners.

Comparison to Industry Standards

• The re-domiciliation is a strategic move to align Bionomics with US-based pharmaceutical companies, which are often listed on Nasdaq.
• The exchange ratio is designed to ensure that the company meets Nasdaq's minimum listing requirements.
• The Sale Facility for Small Parcel Holders is a measure to address the unique structure of Bionomics' share register, which includes a large number of small shareholders.

Stakeholder Impact

• Shareholders will receive Neuphoria shares or cash proceeds from the Sale Facility.
• The re-domiciliation may increase the company's attractiveness to US investors and strategic partners.
• The company will be subject to US securities laws and reporting requirements.

Next Steps

• Dispatch of the Scheme Booklet to Bionomics shareholders around November 13, 2024.
• Bionomics shareholders to vote at the Scheme Meeting on December 12, 2024.
• Court approval of the Scheme.
• Implementation of the Scheme and listing of Neuphoria shares on Nasdaq.

Key Dates

Keywords

Scheme of Arrangement, Re-domiciliation, Neuphoria Therapeutics, Bionomics Limited, Shareholder Vote, Exchange Ratio, Sale Facility, ADS, Scheme Booklet, Independent Expert